San Jose, CA, November 4, 2021 – BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for high value hard-to-drug therapeutic targets, today announced that Wolf Ruprecht Wiedemeyer, Ph.D., has joined the Company as Biology Director. A cancer biologist, Dr. Wiedemeyer comes to BridGene with a deep understanding of cell biology, in vivo models and genomics.
Dr. Wiedemeyer will lead biology research activities focusing on BridGene’s advancing and expanding pipeline as well as the discovery and development of innovative small molecules that provide new paths to treat diseases.
“The depth of Dr. Wiedemeyer’s knowledge and insight into biology and drug development, and how they relate to oncology, will play an invaluable role in helping BridGene in finding and advancing drugs at previously undruggable targets,” stated Ping Cao, Ph.D., Co-Founder and CEO of BridGene Biosciences.
Prior to BridGene, Dr. Wiedemeyer held positions as Principal Scientist within AbbVie Oncology Discovery. There, he led a team of researchers in developing, maintaining and characterizing patient-derived xenograft (PDX) models of ovarian, gastric, colorectal and non-small cell lung cancer. Prior to joining AbbVie, Dr. Wiedemeyer was a Research Scientist and Assistant Professor at Cedars-Sinai Medical Center/UCLA, where his lab focused on novel therapeutic strategies for high-grade serious ovarian cancer and basal-like breast cancer.
Dr. Wiedemeyer has published more than 30 research papers with a focus on cell cycle regulation and mechanisms of drug resistance. He completed a postdoctoral fellowship at the Dana-Farber Cancer Institute/Harvard Medical School and received a Ph.D. from the German Cancer Research Center in Heidelberg, Germany.
About BridGene Biosciences
BridGene is a biotechnology company focused on discovering and developing innovative small molecules that drug traditionally undruggable targets, providing new paths to treat diseases. By using its proprietary chemoproteomic platform, IMTAC™, BridGene is able to screen small molecules against all proteins in live cells to discover drug candidates for high value and previously undruggable targets. For this purpose, BridGene takes advantage of its proprietary, diverse library of tagged, drug-like small molecules. The ultimate goal is to enable breakthrough small-molecule drug discovery and to expand the mechanisms to treat diseases, with targets previously inaccessible to small molecules. BridGene can perform IMTAC screening for both covalent and non-covalent molecules and discover new targets for disease treatments by deconvoluting phenotypic screening hits, setting the company apart from its peers. The company is advancing a diversified pipeline of first-in-class drugs for targets in multiple disease areas. For more information, visit http://bridgenebio.com/.
Lisa Sher (investors)
David Schemelia (media)